Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta.

Source:http://linkedlifedata.com/resource/pubmed/id/10064594

EMBO J. 1999 Mar 1 18 5 1280-91

Download in:

View as

General Info

PMID
10064594